Inflammasomes are multiprotein complexes that can sense pathogen-associated molecular patterns and damage-associated molecular signals. They are involved in the initiation and development of inflammation via activation of IL-1β and IL-18. Many recent studies suggest a strong correlation between inflammasomes and neurological diseases, such as multiple sclerosis (MS), Alzheimer’s disease (AD), and Parkinson’s disease (PD). Several components of inflammasomes, such as nucleotide-binding oligomerization domain- (NOD-) like receptor, absent in melanoma 2- (AIM2-) like receptors (ALRs), apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), and caspase-1, as well as the upstream factors and downstream effectors, are associated with the initiation and development of MS and its animal model, experimental autoimmune encephalomyelitis. Additionally, inflammasomes affect the efficacy of interferon-β therapy in patients with MS. Finally, the strong association of inflammasomes with AD and PD needs to be further studied. In this review of latest literatures, we comprehensively tease out diverse roles of different kinds of inflammasomes in neuroimmune and neurodegenerative diseases, especially in the perspective of double roles involved in pathogenesis, and identify future research priorities.

1. Introduction

Inflammasomes are multiprotein complexes with an inherent ability to elicit innate immune responses by sensing damage signals and microbial attack [1]. Inflammasomes exist in the cytosol of several types of cells, including immune cells (such as T cells, B cells, dendritic cells, and macrophages), neural cells [2], microglia [3], and astrocytes [4] as well as pulmonary endothelial cells [5]. Inflammasomes play a critical role in the development of neurological, immune, and neurodegenerative diseases, such as multiple sclerosis (MS), Alzheimer’s disease (AD), and Parkinson’s disease (PD). The multimeric complexes in inflammasomes have classically been referred to as “damage sensors,” since nucleotide-binding oligomerization domain- (NOD-) and absent in melanoma 2- (AIM2-) like receptors recognize and interact with pathogen-associated molecular patterns, which in turn trigger a series of immune reactions. Recently, there has been an increase in the research on inflammasomes. Several studies have documented the increased inflammasome components and inducing factors, such as adenosine triphosphate (ATP) and uric acid, during the development of MS and experimental autoimmune encephalomyelitis (EAE), an animal model of MS. In this work, we provide a comprehensive overview of the role of inflammasomes in neuroimmune and neurodegenerative diseases based on a review of contemporary literature.

2. Structure and Function of Inflammasomes

Inflammasomes contain three components: sensors, apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), and an enzymatic component. Based on the structural features, sensors can be classified into three types: NOD-like receptors (NLRs), AIM2-like receptors (ALRs), and pyrin. The sensors have the ability...
to detect pathogen-associated molecular patterns (PAMPs) [6] or damage-associated molecular patterns (DAMPs) and cytosolic double-stranded DNA [7]. Detection of these stimuli triggers the assembly of the three components based on the nucleating ability of the pyrin domain (PYD) and the caspase recruitment domain (CARD) [8, 9]. The assembled complexes act as proteolytic cleavers which activate the precursor of interleukin-1β (IL-1β) and IL-18, which are involved in a series of immune and inflammatory processes [10–12]. The NLR family, pyrin domain-containing 1 [13], 3 [14], 4 [15], and 12 [16] (NLRP1, NLRP3, NLRP4, and NLRP12, resp.), are NLRs that have been shown to be involved in inflammasome assembly, while AIM2 is the most well-characterized ALR. AIM2 detects DNA through a HIN domain [17], while NLRP3 [18] detects intracellular DNA by the stimulator of IFN genes- (STING-) mediated DNA-sensing pathway [18]. In general, IL-1β is cleaved by caspase-1. However, some previous studies also indicated that IL-1β can be processed by caspase-8 [19] or caspase-11 through a noncanonical inflammasome [20].

Most inflammasomes promote inflammation by inducing production of inflammatory factors IL-1β and IL-18. However, some inflammasomes also have anti-inflammatory effects. The inhibitory effect of NLRX1 on microglial-induced inflammation in EAE was first reported by Eitas et al. [21]. Moreover, inflammasomes are capable of maintaining the balance of the gut microflora and prevent enteritis from progressing to a tumor [22].

3. Factors Involved in Inflammasome Activation and Regulation

Since inflammasomes lower the threshold of immune response [23], the search for the factors involved in their activation and regulation aiming at identifying therapeutic targets against autoimmune disease has evoked much interest. The initiation of inflammasomes is not well characterized; however, the following mechanism of activation of NLRP3 has been described: First, the bacterial or viral RNA [24], ATP [25], uric acid crystals [26], silica [27], and other similar factors interact with toll-like receptors (TLRs), NOD2, TNFR1, or TNFR2 to induce a cellular expression of NLRP3. Second, PAMP or DAMP triggers NLRP3 to initiate inflammasome formation. In the first stage, P2X7/P2X4 has been shown to be a receptor of ATP [28], whereas pannexin 1 (Panx1) mediates the release of ATP from cells [29]. P2X(4) receptors are another important signal that activates inflammasomes. It has been reported that P2X(4) influences NLRP1 inflammasome signaling in spinal cord injury [30] and osteoarthritis [31]. Moreover, biglycan, a kind of leucine-rich repeat proteoglycan, can also activate NLRP3 inflammasomes through interaction with TLR2/4 and purine P2X4/P2X7 receptors on macrophages [32]. Antiapoptotic proteins, activated T cells, and microRNAs are negative regulators of inflammasomes [33]. Tumor necrosis factor (TNF) α-induced protein 3 (TNFAIP3) and the binding of antiapoptotic proteins Bcl-2 and Bcl-X(L) have been shown to dampen the NLRP1 inflammasome [34, 35]. NF-κB is also one of the activation signals for inflammasomes [36]. Atorvastatin was shown to suppress inflammasomes in monocytes via the TLR4/MyD88/NF-κB pathway [37]. The myeloid-specific microRNAs, miR-223 and miR-7, suppress NLRP3 inflammasome activity via inhibition of NLRP3 protein expression [38, 39]. Mouse effector and memory CD4+ T cells were shown to suppress inflammasomes of macrophages via cell-to-cell contact [40]. Human CD4+ memory T cells suppress NLRP3 activation by down-regulating P2X7R signaling [41]. Furthermore, it has been reported that caspase-12 associated with caspase-1 inhibits its activity [42]. In addition, polyoxotungstate-1 (POM-1) can inhibit the events related with ATP-dependent inflammasome activation [43]. Probenecid, a Panx1 inhibitor, protects against oxygen-glucose deprivation injury in primary astrocytes by regulating inflammasome activity [44]. Moreover, one interesting finding is that in primary macrophage cultures, low intracellular K(+) and the membrane channel Panx1 induce inflammasome activation, while in the primary neuron and astrocyte cultures, high extracellular potassium opens Panx1 channels leading to caspase-1 and inflammasome activation [45]. The reason for this discrepancy is still unclear; it is surmised that there might be an unknown factor suppressing caspase-1. Factors that negatively regulate inflammasome activity are shown in Table 1.

4. Inflammasomes in MS/EAE

MS is an immune-mediated, chronic inflammatory demyelinating disease of the central nervous system (CNS). The hallmark of MS is recurrent neurological dysfunction and a progressive disease course. EAE is an animal model of MS [46] that is characterized by mononuclear cell infiltration around small vessels and demyelination in CNS mediated by specific sensitized CD4+ T cells. Dumas et al. [47] demonstrated that the pertussis toxin could promote the formation of a pyrin-dependent inflammasome in EAE. Elevated levels of IL-1β have also been reported in the cerebrospinal fluid (CSF) of MS patients before clinical relapse, and caspase-1 expression is detected in MS plaques [48].

EAE mice with NLRP3 gene knockout experienced a different disease course. The NLRP3−/− mice had a significantly delayed disease course and less severe disease [49]. Subsequently, the higher dose of immunizing agents in ASC−/− and NLRP3−/− mice implies that inflammasomes are involved in the progression of EAE. Additionally, the amount of inflammasome-associated protein mRNA, such as in NLRP1, caspase-1, caspase-3, ASC, and pro-IL-1β, were shown to be elevated 2 weeks after injection of myelin oligodendrocyte glycoprotein peptide [13, 50–53]. In a chlorpromazine- (CPZ-) induced demyelination mouse model, the progesterone treatment group exhibited a decrease in neurological behavioral deficit scores accompanied by decreased levels of NLRP3 inflammasomes [54]. This research suggests that NLRP3 inflammasomes are involved in the pathogenesis of the CPZ-induced demyelination mouse model. Moreover, the occurrence of MS-like symptoms in patients with other autoimmune diseases and inflammasome-associated genetic mutations indicates that
Inflammasomes are involved in the pathogenesis of MS. For example, mutations of the pyrin domain of Mediterranean fever gene (MEFV gene) have been linked to a higher susceptibility to more progressive or severe MS [55–57]. Patients with familial Mediterranean fever who have CAPS-associated V198M and Q703K mutations tend to experience Muckle-Wells syndrome showed MS-like pathology [59, 60]. Moreover, IL-1 expression and IL-18 were shown to promote autoimmunity by stimulating innate IL-17 production by T cells [77], and the increased levels of serum IL-18 in patients with MS illustrate its key role in the pathogenesis of MS [78].

Th1 and Th17 cells are critical to the progress of EAE [79], and the inflammasomes were shown to induce EAE via modulation of their autoimmune response. Gris et al. [49] demonstrated that NLRP3 could possibly impair Th1 and Th17 responses by affecting caspase-1-dependent cytokines, and hence, NLRP3 could induce EAE. However, there are conflicting views pertaining to the role of Th17 inflammasomes in the NLRP3+/− and ASC+/− mouse EAE models. Inoue et al. [80] reported that reduction in Th17 is not crucial for a reduced clinical score in the NLRP3+/− and ASC+/− mouse EAE models.

Moreover, inflammasomes could also enhance EAE by affecting Th1 and Th17 immigration to the CNS. Inoue et al. reported that NLRP3 inflammasomes do not induce an increase in the population of Th17 cells; instead, they contribute to T cell chemotactic activity in the CNS [80]. During the process, CD4+ T cells are activated by IL-1β and IL-18 produced by antigen-presenting cells (dendritic cells and macrophages), which have copious amounts of inflammasomes; as a consequence, there is an increase in the expression levels of chemotaxis-related proteins (such as osteopontin, CCR2, and CXCR6) [80].

In addition, inflammasomes are the cofactor of some substances that are involved in EAE pathogenesis, such as integrin-associated protein (IAP) CD47 and Panx1. In vivo administration of exogenous IL-1β has been shown to promote the infiltration of CD47+/− Th17 cells into the CNS. Mechanically, blocking of CD47 activates Src, subsequently inducing and then decreasing the degradation level of inducible nitric oxide synthase. As a result, the level of nitric oxide (NO) increases and suppresses inflammasome activation-induced IL-1β production. As mentioned previously, lower IL-1β reduces the expressions of IL-1R and migration-related chemokine receptors on Th17 cells, thereby suppressing EAE development [81].

The reason why the plasma membrane channel Panx1 could contribute to EAE progression is that Panx1 mediates ATP release and further triggers inflammasome activation [82].

### Table 1: The negative regulation factors of inflammasomes

| Regulation of factors | Target       | Mechanism                                                                 |
|-----------------------|--------------|---------------------------------------------------------------------------|
| A20/TNFAIP3 [34]      | NLRP1        | Binding with Bcl-2 and Bcl-X(L)                                            |
| miR-223 [38]          | NLRP3        | Acting on a conserved binding site within 3’ untranslated region of NLRP3 |
| miR-7 [39]            | NLRP3        | Posttranscriptionally controlled NLRP3 expression                         |
| Human CD4+ memory T cells [41] | NLRP3 | Down-regulation of P2X7R signaling molecules                              |
| Caspase-12 [42]       | Caspase-1    | Associated with caspase-1                                                 |
| POM-1 [43]            | NLRP1        | Inhibit the events related with ATP-dependent inflammasome                |
| Probencid [44]        | NLRP3        | Block pannexin 1 channel and high extracellular potassium                 |
| Type I interferons [86]| NLRP1/NLRP3 | Via the STAT1 transcription factor                                         |

A20/TNFAIP3: tumor necrosis factor α-induced protein 3; NLRP1/NLRP3: NOD-like receptors pyrin domain-containing 1 or 3; POM-1: polyoxotungstate-1.
Interestingly, inflammasomes have been evidenced to excrete exosomes acting on nearby macrophages and activating the NF-κB signal pathway, which may enhance the immune response in autoimmune diseases [83]. These findings regarding the mechanism of inflammasomes involved in inflammation may give new insights into the pathogenesis of MS/EAE. The inflammasomes and factors involved in MS/EAE are shown in Figure 1.

6. Inflammasomes and the Role of IFNγ and IFNβ in EAE

According to Inoue et al., EAE can be of two types: type A which is NLRP3-dependent and type B, which is NLRP3-independent and resistant to interferon-β (IFNβ) treatment [84]. Type B EAE accounts for one-third of all EAE animals [85]. The two subtypes are amenable to alteration during EAE development.

IFNβ is effective in relapsing-remitting multiple sclerosis (RRMS) via inhibition of NLRP3 [84, 86]. Type I interferon was shown to inhibit NLRP1/NLRP3 inflammasome and then reduce the expression levels of pro-IL-1β/pro-IL-18 [86]. Besides, binding of IFNβ with IFN receptor I on antigen-presenting cells (APCs) inhibits suppression of cytokine signaling (SOCS), which can downregulate a member of the Rho family of GTPases, Rac1, guanosine triphosphate (Rac1-GTP), through SOCS-1 and induce generation of reactive oxygen species (ROS) [84]. The increase in ROS level is conducive to activation of inflammasomes. However, these mechanisms do not work on NLRC4 inflammasomes. Moreover, there is proof of involvement of the other inflammasome components in the pathogenesis of MS: NOD2 gene polymorphism rs5743291 was shown to activate Th2 and Th17 cells in patients with MS [87]. Further, targeting of NOD2 pathways with a NOD2-activating agent, MIS416, was shown to modulate the Th response and alleviate EAE [88].

In a study by Noroozi et al., MS patients treated with IFNβ experienced a decrease in plasma IL-1β levels as well as the expressions of NLRP3, NLRC4, and AIM2 in peripheral blood mononuclear cells [89]. Similar results have been reported from a study by Malhotra et al.: MS patients who responded well to IFNβ showed lower mRNA levels of NLRP3 and IL-1β as compared to their pretreatment levels; conversely, nonresponders experienced upregulation of NLRP3 and IL-1β mRNA levels after three months of treatment with IFNβ [90]. The underlying mechanism of resistance of the NLRP3 inflammasome-independent pattern to IFNβ treatment is not completely understood. However, Inoue et al. [91] have shown that membrane-bound lymphotixin and the chemokine receptor CXCR are involved in this process and antagonizing these receptors ameliorates NLRP3-independent EAE.

7. The Targets of Treatment in MS/EAE

Owing to the key role of inflammasomes in the development of EAE or MS, research on the means to inhibit their function

---

**Figure 1**: Inflammasomes and factors involved in the pathogenesis of MS/EAE. NLRP3 inflammasomes convert pro-IL-1β and pro-IL-18 to IL-1β and IL-18. IL-18 stimulates CD4+ T cells to produce IL-17; NLRP3 inflammasomes contribute to T cell chemotactic activity in the CNS; IL-1β induces the differentiation of Th17 cells and promotes them infiltrate into the CNS; IL-1β also induces the production of GM-CSF, which is an important factor in T cell encephalitogenicity. IL-1β: interleukin-1β; IL-18: interleukin-18; IL-17: interleukin-17; NLRP3: NOD-like receptor pyrin domain-containing 3; ASC, apoptosis-associated speck-like protein containing a caspase recruitment domain; BBB: blood-brain barrier; GM-CSF: granulocyte-macrophage colony-stimulating factor.
is of much clinical relevance. The upstream factors and downstream effectors of inflammasomes are attractive therapeutic targets in the context of EAE/MS. JC-171, a hydroxyl sulfonamide analogue, which is a selective NLRP3 inflammasome inhibitor, has been shown to exhibit preventive and therapeutic effects in the EAE setting [92]. In a study by Coll et al. [93], MCC950 (a diarylsulfonylurea-containing compound that inhibits IL-1β) was shown to specifically inhibit canonical and noncanonical NLRP3 activation in EAE. Moreover, as Gao et al. [81] described that CD47-Fc fusion protein, the inhibitor of CD47, which is capable of inducing NO production that suppresses inflammasome activation-induced IL-1β expression, could also prevent and ameliorate EAE. Similarly, cladribine, an adenosine deaminase inhibitor, was shown to suppress excitatory postsynaptic currents induced by IL-1β, which has been proven to be one of the mechanisms for treatment of MS [94]. Furthermore, NLRP3 is involved in mediating the therapeutic effect of prednisone [95], cannabinoid receptor 2 (CB2R) [96], and periodontal ligament stem cells [97] in EAE.

8. Inflammasomes in Alzheimer’s Disease

Alzheimer’s disease (AD) is a neurodegenerative disease characterized by progressive cognitive impairment. It accounts for 50% to 70% of cases with dementia in the elderly [98] and is viewed as one of the great health-care challenges of the 21st century [99]. However, there is no effective cure to halt the progress of this disease [99]. AD is pathologically characterized by Aβ deposit. The Aβ deposit and damage-associated molecular pattern molecules (DAMPs) released by the subsequent neuronal injury are sensed by inflammasomes, which initiates an innate immune response [100, 101]. The messenger RNA (mRNA) levels of the NLRP1 and NLRP3 components increase in AD [102]. NLRP1 induces caspase-1 and caspase-6, and this pathway is involved in the progression of AD [103]. In addition to exhibiting lower caspase-1 and IL-1β activity levels and enhanced Aβ clearance, NLRP3−/− mice display better memory than do NLRP3 wild-type mice. Moreover, knocking down NLRP3 promotes M1-type microglial bias to the M2 type. This helps in Aβ clearance and tissue remodeling in the APP/PS1 model as M2-type microglia are efficient at phagocytosis [104]. The mechanism of activation of NLRP3 is yet to be clarified; however, in microglia, NLRP3 inflammasomes were shown to be activated not only by Aβ via the TLR4-MyD88-MyD88-MyD88 pathway in microglia but also by P2X7R as in the EAE model and cathepsin B (CTSB). In addition, NLRP10, another NOD-like receptor, has been shown to attenuate Aβ-induced caspase-1 activation and IL-1β release [105].

The fact that the overexpression of the effectors of inflammasomes, IL-1β and IL-18, initiates the inflammatory process in AD patients verifies the association between inflammasome and AD [106, 107]. Kitazawa et al. demonstrated that the IL-1β signal cascade is an important pathogenic factor of AD; its blockade was shown to ameliorate pathological changes in a mouse model of AD [108]. In a study by Craft et al., knocking out the IL-1β receptor antagonist in a mouse model of AD was shown to aggravate the neuropathological sequelae [109]. The above-mentioned investigations indicate that inhibition of inflammasome activation might be a potential therapeutic target for AD. The inflammasomes involved in AD are shown in Figure 2.

9. Inflammasomes in Parkinson’s Disease

Parkinson’s disease (or paralysis agitans) is a common neurodegenerative disorder, which is characterized by loss of dopaminergic neurons [110] and aggregation of the α-synuclein deposit [111]. Activation of inflammasomes and elevation of serum caspase-1 and IL-1β levels have been demonstrated in nigrostriatal DA regions of the PD mouse model as well as in the brain and cerebrospinal fluid of PD patients [112–114]. Inflammasomes could be activated by oxidative stress and excessive activated microglia, both of which play an important role in the pathogenesis of PD. To be specific, oxidative stress from ROS activates NLRP3 through c-Abl kinase or upregulates CTSB activity in microglial cells [115, 116]. Additionally, cyclin-dependent kinase 5 (Cdk5) is also an essential factor for activation of inflammasomes in neurons [114]. Caspase-1- and caspase-3-related apoptotic cell death is a crucial link, through which epidemiological risk factors such as MPP (+), paraquat, dieldrin, and salsolinol can cause PD [117, 118]. Furthermore, caspase-1 could directly cleave α-synuclein into a highly aggregation-prone variant, which subsequently forms aggregated α-synuclein and assaults neurons [119]. Noteworthily, despite of the correlation between caspase-1 and PD, caspase-1 inhibitors may not be the determining factor of dopaminergic neuronal death in vitro, or the efficacy of caspase-1 inhibitors may depend on the extent of apoptotic stress [120]. Specifically, caspase-1 inhibitors did not improve the survival of grafted dopaminergic neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- (MPTP-) induced PD models [120], and caspase-1 inhibitors could not prevent dopaminergic neuronal death in MPTP parkinsonian mice [121].

The function of NLRP3 and caspase-1 is closely related to α-synuclein, the pathogenic factor of PD. α-Synuclein activates the toll-like receptor 2 (TLR2) that promotes the assembly of NLRP3 [122] and induces synthesis of IL-1β [123]. The increase in IL-1β expression level induces production of ROS and release of CTSB, which in turn activates NLRP3 [115, 123]. Besides, α-synuclein was shown to promote both TLR4/NF-κB and NLRP3/caspase-1 signals in adult neural stem cells (ANSCs), and both NLRP3 knockdown and caspase-1 deficiency reverse the antiapoptotic effect of α-synuclein on ANSCs [39]. In terms of the treatment of PD, pharmacological inhibitions for inflammasome activation-related molecules, such as caspase-1, microRNA-7, CTSB, c-Abl, and Cdk5, may open up novel therapeutic avenues. The inflammasomes involved in PD are shown in Figure 2.

10. Closing Remarks

Inflammasomes are supramolecular signaling complexes involved in the inflammatory process. They consist of three
components: sensors, ASC, and caspases. There are subvariants of sensors and caspases, such as NLRP1, NLRP3, caspase-1, and caspase-4, marking variable inflammasomes with different biological functions. Most of the inflammasomes contribute to the development of neuroimmune and neurodegenerative diseases such as the NLRP3 inflammasome, while some have anti-inflammatory properties such as NLRX1 inflammasome and NLRP12 inflammasome. In the pathogenesis of MS/EAE, inflammasomes promote Th1 and Th17 cells migrating into CNS. Furthermore, they enhance the immune response in EAE by secreting exosomes to act on nearby macrophages. In patients and animal models of AD and PD, the component of inflammasomes, such as caspase-1, and the effector IL-1β and IL-18, all can aggravate the Aβ- or α-synuclein-induced pathological process. Though substantial evidence has proved the vital roles of inflammasomes, the exact mechanism underlying inflammatory reactions in these disorders is yet to be fully understood. Theoretically, inflammasome antagonists may exhibit a protective effect on the patients with neuroimmune or neurodegenerative disorders via multiple pathways. Nevertheless, the efficacy of inflammasome-targeted therapies still needs further investigations. In addition, the exact pathogenesis of NLRP3-independent MS is still unclear.

Finally, the most reported inflammasomes involved in the pathogenesis of neuroimmune and neurodegenerative diseases are NLRP3 and NLRP1; whether other inflammasomes are potential important factors contributing to these disorders is worth studying in the future.

**Abbreviations**

| Acronym | Definition |
|---------|------------|
| AD      | Alzheimer’s disease |
| ALRs    | AIM2-like receptors |
| ANSCs   | Adult neural stem cells |
| APCs    | Antigen-presenting cells |
| ASC     | Apoptosis-associated speck-like protein containing a caspase recruitment domain |
| ATP     | Adenosine triphosphate |
| CARD    | Caspase recruitment domain |
| CB2R    | Cannabinoid receptor 2 |
| CNS     | Central nervous system |
| CPZ     | Chlorpromazine |
| CSF     | Cerebrospinal fluid |
| DAMPs   | Damage-associated molecular patterns |
| EAE     | Experimental autoimmune encephalomyelitis |
| IAP     | Integrin-associated protein |
| IFNβ    | Interferon-β |
IL-1β: Interleukin-1β
mRNA: Messenger RNA
MS: Multiple sclerosis
NLRs: NOD-like receptors
NLRP3: NOD-like receptor pyrin domain-containing 3
NO: Nitric oxide
NOD: Nucleotide-binding oligomerization domain
PAMPs: Pathogen-associated molecular patterns
PD: Parkinson’s disease
POM-1: Polyoxotungstate-1
PYD: Pyrin domain
Rac1-GTP: Rac1-guanosine triphosphate
ROS: Reactive oxygen species
TLRs: Toll-like receptors
TNF: Tumor necrosis factor
TNFAP13: Tumor necrosis factor α-induced protein 3
TRAF: TNF receptor-associated factor
SOCS: Suppressor of cytokine signaling.

Conflicts of Interest
The authors declare that they have no competing interests.

Acknowledgments
This study was supported by grants from The First Hospital, Jilin University, Changchun, China, and from the National Natural Science Foundation (nos. 8167050314, 81471216, 81671186, 81671177, 31600820, and 2017030) as well as from the Swedish Research Council (K2013-66X-22337-01-3 and project with 2015-03005).

References
[1] M. Lamkanfi and V. M. Dixit, “Mechanisms and functions of inflammasomes,” Cell, vol. 157, no. 5, pp. 1013–1022, 2014.
[2] S. E. Adamczak, J. P. de Rivero Vaccari, G. Dale et al., “Pyroptotic neuronal cell death mediated by the AIM2 inflammasome,” Journal of Cerebral Blood Flow & Metabolism, vol. 34, no. 4, pp. 621–629, 2014.
[3] U. K. Hanisch, “Microglia as a source and target of cytokines,” Glia, vol. 40, no. 2, pp. 140–155, 2002.
[4] J. Minkiewicz, J. P. de Rivero Vaccari, and R. W. Keane, “Human astrocytes express a novel NLRP2 inflammasome,” Glia, vol. 61, no. 7, pp. 1113–1121, 2013.
[5] M. Xiang, X. Shi, Y. Li et al., “Hemorrhagic shock activation of NLRP3 inflammasome in lung endothelial cells,” The Journal of Immunology, vol. 187, no. 9, pp. 4809–4817, 2011.
[6] C. Basset, J. Holton, R. O’Mahony, and I. Roitt, “Innate immunity and pathogen–host interaction,” Vaccine, vol. 21, Supplement 2, pp. S12–S23, 2003.
[7] T. Fernandes-Alnemri, J. W. Yu, P. Datta, J. Wu, and E. S. Alnemri, “AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA,” Nature, vol. 458, no. 7237, pp. 509–513, 2009.
[8] A. Lu, V. G. Maguapalli, J. Ruan et al., “Unified polymerization mechanism for the assembly of ASC-dependent inflammasomes,” Cell, vol. 156, no. 6, pp. 1193–1206, 2014.
[9] L. Sborgi, F. Ravotti, V. P. Dandey et al., “Structure and assembly of the mouse ASC inflammasome by combined NMR spectroscopy and cryo-electron microscopy,” Proceedings of the National Academy of Sciences of the United States of America, vol. 112, no. 43, pp. 13237–13242, 2015.
[10] I. Jorgensen and E. A. Miao, “Pyroptotic cell death defends against intracellular pathogens,” Immunological Reviews, vol. 265, no. 1, pp. 130–142, 2015.
[11] C. E. Sutton, S. J. Lalor, C. M. Sweeney, C. F. Brereton, E. C. Lavelle, and K. H. G. Mills, “Interleukin-1 and IL-23 induce innate IL-17 production from γδ T cells, amplifying Th17 responses and autoimmunity,” Immunity, vol. 31, no. 2, pp. 331–341, 2009.
[12] S. Karakas Celik, Z. S. Oz, A. Dursun et al., “Interleukin 18 gene polymorphism is a risk factor for multiple sclerosis,” Molecular Biology Reports, vol. 41, no. 3, pp. 1653–1658, 2014.
[13] B. Faustin, L. Dartigue, J. M. Bruey et al., “Reconstituted NALP1 inflammasome reveals two-step mechanism of caspase-1 activation,” Molecular Cell, vol. 25, no. 5, pp. 713–724, 2007.
[14] A. R. Shenoy, D. A. Wellington, P. Kumar et al., “GBP5 promotes NLRP3 inflammasome assembly and immunity in mammals,” Science, vol. 336, no. 6080, pp. 481–485, 2012.
[15] Y. Qu, S. Misaghi, A. Izrael-Tomasevic et al., “Phosphorylation of NLRC4 is critical for inflammasome activation,” Nature, vol. 490, no. 7421, pp. 539–542, 2012.
[16] G. I. Vladimer, D. Weng, S. W. M. Paquette et al., “The NLRP12 inflammasome recognizes Yersinia pestis,” Immunity, vol. 37, no. 1, pp. 96–107, 2012.
[17] S. E. Warren, A. Armstrong, M. K. Hamilton et al., “Cutting edge: cytosolic bacterial DNA activates the inflammasome via Aim2,” The Journal of Immunology, vol. 185, no. 2, pp. 818–821, 2010.
[18] D. Kwon, E. Park, and S. J. Kang, “Stimulator of IFN genes–mediated DNA-sensing pathway is suppressed by NLRP3 agonists and regulated by mitofusin 1 and TBC1D15, mitochondrial dynamics mediators,” The FASEB Journal, vol. 31, no. 11, pp. 4866–4878, 2017.
[19] C. Antonopoulos, H. M. Russo, C. El Sanadi et al., “Caspase-8 as an effector and regulator of NLRP3 inflammasome signaling,” The Journal of Biological Chemistry, vol. 290, no. 33, pp. 20167–20184, 2015.
[20] N. Kayagaki, S. Warming, M. Lamkanfi et al., “Non-canonical inflammasome activation targets caspase-11,” Nature, vol. 479, no. 7371, pp. 117–121, 2011.
[21] T. K. Eitas, W. C. Chou, H. Wen et al., “The nucleotide-binding leucine-rich repeat repeat (NLR) family member NLRX1 mediates protection against experimental autoimmune encephalomyelitis and represses macrophage/microglia-induced inflammasome,” Journal of Biological Chemistry, vol. 289, no. 7, pp. 4173–4179, 2014.
[22] I. C. Allen, E. M. E. TeKippe, R. M. T. Woodford et al., “The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer,” Journal of Experimental Medicine, vol. 207, no. 5, pp. 1045–1056, 2010.
[23] C. A. Yang and B. L. Chiang, “Inflammasomes and human autoimmunity: a comprehensive review,” Journal of Autoimmunity, vol. 61, pp. 1–8, 2015.
[24] W. Sha, H. Mitoma, S. Hanabuchi et al., “Human NLRP3 inflammasome senses multiple types of bacterial RNAs,”
Mediators of Inflammation

Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 45, pp. 16059–16064, 2014.

[25] S. Mariathasan, D. S. Weiss, K. Newton et al., “Cryopyrin activates the inflammasome in response to toxins and ATP,” Nature, vol. 440, no. 7081, pp. 228–232, 2006.

[26] F. Martinon, V. Péttrilli, A. Mayor, A. Tardivel, and J. Tschopp, “Gout-associated uric acid crystals activate the NALP3 inflammasome,” Nature, vol. 440, no. 7081, pp. 237–241, 2006.

[27] V. Hornung, F. Bauerfeind, A. Halle et al., “Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization,” Nature Immunology, vol. 9, no. 8, pp. 847–856, 2008.

[28] B. N. Martin, C. Wang, C. J. Zhang et al., “T cell–intrinsic ASC critically promotes T<sub>p</sub>H<sub>17</sub>-mediated experimental autoimmune encephalomyelitis,” Nature Immunology, vol. 17, no. 5, pp. 583–592, 2016.

[29] S. E. Adamson and N. Leitinger, “The role of pannexin1 in the induction and resolution of inflammation,” FEBS Letters, vol. 588, no. 8, pp. 1416–1422, 2014.

[30] J. P. de Rivera Vaccari, D. Bastien, G. Yurcisin et al., “P2X<sub>4</sub> receptors influence inflammasome activation after spinal cord injury,” The Journal of Neuroscience, vol. 32, no. 9, pp. 3058–3066, 2012.

[31] C. Fan, X. Zhao, X. Guo, X. Cao, and J. Cai, “P2X4 promotes interleukin-1β production in osteoarthritis via NLRP1,” Molecular Medicine Reports, vol. 9, no. 1, pp. 340–344, 2014.

[32] S. Chen and B. Sun, “Negative regulation of NLRP3 inflammasome signaling,” Protein & Cell, vol. 4, no. 4, pp. 251–258, 2013.

[33] J. M. Bruey, N. Bruey-Sedano, F. Luciano et al., “Bcl-2 and Bcl-x<sub>L</sub> regulate proinflammatory caspase-1 activation by interaction with NALP1,” Cell, vol. 129, no. 1, pp. 45–56, 2007.

[34] L. V. Walle, N. van Opdenbosch, P. Jacques et al., “Negative regulation of the NLRP3 inflammasome by A20 protects against arthritis,” Nature, vol. 512, no. 7512, pp. 69–73, 2014.

[35] T. Eigenbrod, K. A. Bode, and A. H. Dalpkne, “Early inhibition of IL-1β expression by IFN-γ is mediated by impaired binding of NF-κB to the IL-1β promoter but is independent of nitric oxide,” The Journal of Immunology, vol. 190, no. 12, pp. 6533–6541, 2013.

[36] J. F. Kong, B. Z. Ye, L. Lin, X. Cai, W. Huang, and Z. Huang, “Atorvastatin suppresses NLRP3 inflammasome activation via TLR4/MyD88/NF-κB signaling in PMA-stimulated THP-1 monocyes,” Biomedicine & Pharmacotherapy, vol. 82, pp. 167–172, 2016.

[37] S. Bauernfeind, A. Rieger, F. A. Schildberg, P. A. Knolle, J. L. Schmidt-Burgk, and V. Hornung, “NLRP3 inflammasome activity is negatively controlled by miR-223,” The Journal of Immunology, vol. 189, no. 8, pp. 4175–4181, 2012.

[38] Z. Fan, M. Lu, C. Qiao, Y. Zhou, J. H. Ding, and G. Hu, “MicroRNA-7 enhances subventricular zone neurogenesis by inhibiting NLRP3/caspase-1 axis in adult neural stem cells,” Molecular Neurobiology, vol. 53, no. 10, pp. 7057–7069, 2016.

[39] G. Guarda, C. Dostert, F. Staehli et al., “T cells dampen innate immune responses through inhibition of NLRP1 and NLRP3 inflammasomes,” Nature, vol. 460, no. 7252, pp. 269–273, 2009.

[40] V. Beynon, F. J. Quintana, and H. L. Weiner, “Activated human CD4+CD45RO+ memory T-cells indirectly inhibit NLRP3 inflammasome activation through downregulation of P2X7R signalling,” PLoS One, vol. 7, no. 6, article e39576, 2012.

[41] M. Saleh, J. C. Mathison, M. K. Wolinski et al., “Enhanced bacterial clearance and sepsis resistance in caspase-12-deficient mice,” Nature, vol. 440, no. 7087, pp. 1064–1068, 2006.

[42] G. Pimenta-dos-Reis, E. J. L. Torres, P. G. Quintana et al., “POM-1 inhibits P2 receptors and exhibits anti-inflammatory effects in macrophages,” Purinergic Signa, vol. 13, no. 4, pp. 611–627, 2017.

[43] Z. Jian, S. Ding, H. Deng et al., “Probenecid protects against oxygen–glucose deprivation injury in primary astrocytes by regulating inflammasome activity,” Brain Research, vol. 1643, pp. 123–129, 2016.

[44] W. R. Silverman, J. P. de Rivera Vaccari, S. Locovei et al., “The pannexin 1 channel activates the inflammasome in neurons and astrocytes,” Journal of Biological Chemistry, vol. 284, no. 27, pp. 18143–18151, 2009.

[45] E. Bettelli, “Building different mouse models for human MS,” Annals of the New York Academy of Sciences, vol. 1103, no. 1, pp. 11–18, 2007.

[46] A. Dumas, N. Amiable, J. P. de Rivera Vaccari et al., “The inflammasome pyrin contributes to pertussis toxin-induced IL-1β synthesis, neutrophil intravascular crawling and autoimmune encephalomyelitis,” PLoS Pathogens, vol. 10, no. 5, article e1004150, 2014.

[47] R. Furlan, M. Filippi, A. Bergami et al., “Peripheral levels of caspase-1 mRNA correlate with disease activity in patients with multiple sclerosis; a preliminary study,” Journal of Neurology, Neurosurgery, & Psychiatry, vol. 67, no. 6, pp. 785–788, 1999.

[48] D. Gris, Z. Ye, H. A. Iocca et al., “NLRP3 plays a critical role in the development of experimental autoimmune encephalomyelitis by mediating Th1 and Th17 responses,” The Journal of Immunology, vol. 185, no. 2, pp. 974–981, 2010.

[49] F. Martinon and J. Tschopp, “Inflammatory caspases and inflammasomes: master switches of inflammation,” Cell Death & Differentiation, vol. 14, no. 1, pp. 10–22, 2007.

[50] J. P. de Rivera Vaccari, G. Lotocki, V. D. Dietrich, and R. W. Keane, “A molecular platform in neurons regulates inflammation after spinal cord injury,” The Journal of Neuroscience, vol. 28, no. 13, pp. 3404–3414, 2008.

[51] L. Franchi, T. Eigenbrod, R. Muñoz-Planillo, and G. Nuñez, “The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis,” Nature Immunology, vol. 10, no. 3, pp. 241–247, 2009.

[52] A. M. Souliva, E. Lee, E. McCauley, L. Miers, P. Bannerman, and D. Pleasure, “Initiation and progression of axonopathy in experimental autoimmune encephalomyelitis,” The Journal of Neuroscience, vol. 29, no. 47, pp. 14965–14979, 2009.

[53] R. Arayapour, P. Pasbakhsh, K. Zibara et al., “Progesterone therapy induces an M1 to M2 switch in microglia phenotype...
and suppresses NLRP3 inflammasome in a cuprizone-induced demyelination mouse model,” International Immunopharmacology, vol. 51, pp. 131–139, 2017.

[55] Y. Shinar, A. Livneh, Y. Villa et al., “Common mutations in the familial Mediterranean fever gene associate with rapid progression to disability in non-Askenazi Jewish multiple sclerosis patients,” Genetics & Immunity, vol. 4, no. 3, pp. 197–203, 2003.

[56] A. Ural, A. Dursun, U. Emre, N. F. Tascilar, and H. Ankarali, “Evaluation of common mutations in the Mediterranean fever gene in multiple sclerosis patients: is it a susceptibility gene?,” Journal of the Neurological Sciences, vol. 294, no. 1-2, pp. 38–42, 2010.

[57] G. Yahalom, S. Kivity, M. Lidar et al., “Familial Mediterranean fever (FMF) and multiple sclerosis: an association study critical for its inhibitory function,” Immunology & Cell Biology, vol. 46, no. 4, pp. 709–714, 2007.

[58] L. Fiorentino, C. Stehlik, V. Oliveira, M. E. Ariza, A. Godzik, Y. Shinar, A. Livneh, Y. Villa et al., “G. Yahalom, S. Kivity, M. Lidar et al., “Familial Mediterranean fever (FMF) and multiple sclerosis: an association study critical for its inhibitory function,” Immunology & Cell Biology, vol. 46, no. 4, pp. 709–714, 2007.

[59] I. C. Allen, J. E. Wilson, M. Schneider et al., “A novel PAAD-containing protein that modulates NF-kB induction by cytokines tumor necrosis factor-α and interleukin-1β,” Journal of Biological Chemistry, vol. 277, no. 38, pp. 35333–35340, 2002.

[60] Z. Ye, J. D. Lich, C. B. Moore, J. A. Duncan, K. L. Williams, and J. P. Y. Ting, “ATP binding by monarch-1/NLRP12 is critical for its inhibitory function,” Molecular & Cellular Biology, vol. 28, no. 5, pp. 1841–1850, 2008.

[61] I. C. Allen, J. E. Wilson, M. Schneider et al., “NLRP12 suppresses colon inflammation and tumorgenesis through the negative regulation of noncanonical NF-kB signaling,” Immunity, vol. 36, no. 5, pp. 742–754, 2012.

[62] M. Gharraguzoo, T. M. Mahvelati, E. Imbeault et al., “The nod-like receptor, Nlrp12, plays an anti-inflammatory role in experimental autoimmune encephalomyelitis,” Journal of Neuroinflammation, vol. 12, no. 1, p. 198, 2015.

[63] M. A. Gavrilin, D. H. A. Abdelaziz, M. Mostafa et al., “Activation of the pyrin inflammasome by intracellular Burkholderia cenocepacia,” The Journal of Immunology, vol. 188, no. 7, pp. 3469–3477, 2012.

[64] J. J. Chae, H. D. Komarow, J. Cheng et al., “Targeted disruption of pyrin, the FMF protein, causes heightened sensitivity to endotoxin and a defect in macrophage apoptosis,” Molecular Cell, vol. 11, no. 3, pp. 591–604, 2003.

[65] M. Prins, C. Eriksson, A. Wierincx et al., “Interleukin-1β and interleukin-1 receptor antagonist appear in grey matter additionally to white matter lesions during experimental multiple sclerosis,” PloS One, vol. 8, no. 12, article e83855, 2013.

[66] I. D. Vainchtein, J. Vinet, N. Brouwer et al., “In acute experimental autoimmune encephalomyelitis, infiltrating macrophages are immune activated, whereas microglia remain immune suppressed,” Glia, vol. 62, no. 10, pp. 1724–1735, 2014.

[67] A. E. Russi, M. E. Walker-Caulfield, Y. Guo, C. F. Lucchetti, and M. A. Brown, “Meningeal mast cell-T cell crosstalk regulates T cell encephalitogenicity,” Journal of Autoimmunity, vol. 73, pp. 100–110, 2016.

[68] S. M. Burm, L. A. N. Peferoen, E. A. Zuiderwijk-Sick et al., “Expression of IL-1β in rheus EAE and MS lesions is mainly induced in the CNS itself,” Journal of Neuroinflammation, vol. 13, no. 1, p. 138, 2016.

[69] A. G. Kermode, A. J. Thompson, P. Tofts et al., “Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis: pathogenetic and clinical implications,” Brain, vol. 113, no. 5, pp. 1477–1489, 1990.

[70] A. T. Argaw, Y. Zhang, B. J. Snyder et al., “IL-1β regulates blood-brain barrier permeability via reactivation of the hypoxia-angiogenesis program,” The Journal of Immunology, vol. 177, no. 8, pp. 5574–5584, 2006.

[71] L. P. Shornick, A. K. Bisarya, and D. D. Chaplin, “IL-1β is essential for Langerhans cell activation and antigen delivery to the lymph nodes during contact sensitization: evidence for a dermal source of IL-1β,” Cellular Immunology, vol. 211, no. 2, pp. 105–112, 2001.

[72] A. E. Russi, M. E. Walker-Caulfield, and M. A. Brown, “Mast cell inflammasome activity in the meninges regulates EAE disease severity,” Clinical Immunology, 2016, In press.

[73] Y. Chung, S. H. Chang, G. J. Martinez et al., “Critical regulation of early Th17 cell differentiation by interleukin-1 signaling,” Immunity, vol. 30, no. 4, pp. 576–587, 2009.

[74] A. S. Moraes, R. F. O. Paula, F. Pradella et al., “The suppressive effect of IL-27 on encephalitogenic Th17 cells induced by multivalled carbon nanotubes reduces the severity of experimental autoimmune encephalomyelitis,” CNS Neuroscience & Therapeutics, vol. 19, no. 9, pp. 682–687, 2013.

[75] S. J. Lalor, L. S. Dungan, C. E. Sutton, S. A. Basdeo, J. M. Fletcher, and K. H. G. Mills, “Caspase-1-processed cytokines IL-1β and IL-18 promote IL-17 production by γδ and CD4 T cells that mediate autoimmunity,” The Journal of Immunology, vol. 186, no. 10, pp. 5738–5748, 2011.

[76] F. Nicoletti, R. di Marco, K. Mangano et al., “Increased serum levels of interleukin-18 in patients with multiple sclerosis,” Neurology, vol. 57, no. 2, pp. 342–344, 2001.

[77] J. Zepp, L. Wu, and X. Li, “IL-17 receptor signaling and T helper 17-mediated autoimmune demyelinating disease,” Trends in Immunology, vol. 32, no. 5, pp. 232–239, 2011.

[78] M. Inoue, K. L. Williams, M. D. Gunn, and M. L. Shihohara, “NLRP3 inflammasome induces chemotactic immune cell migration to the CNS in experimental autoimmune encephalomyelitis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 26, pp. 10480–10485, 2012.

[79] Q. Gao, Y. Zhang, C. Han et al., “Blockade of CD47 ameliorates autoimmune inflammation in CNS by suppressing IL-1-triggered infiltration of pathogenic Th17 cells,” Journal of Autoimmunity, vol. 69, pp. 74–85, 2016.

[80] S. E. Lutz, E. González-Fernández, J. C. C. Ventura et al., “Contribution of pannexin1 to experimental autoimmune encephalomyelitis,” PloS One, vol. 8, no. 6, article e66575, 2013.
Mediators of Inflammation

[83] Y. Zhang, F. Liu, Y. Yuan et al., "Inflammasome-derived exosomes activate NF-κB signaling in macrophages," *Journal of Proteome Research*, vol. 16, no. 1, pp. 170–178, 2016.

[84] M. Inoue, K. L. Williams, T. Oliver et al., "Interferon-β therapy against EAE is effective only when development of the disease depends on the NLRP3 inflammasome," *Science Signaling*, vol. 5, no. 225, article ra38, 2012.

[85] B. G. Arnason, "Inmunologic therapy of multiple sclerosis," *Annual Review of Medicine*, vol. 50, no. 1, pp. 291–302, 1999.

[86] G. Guarda, M. Braun, F. Staelhi et al., "Type I interferon inhibits interleukin-1 production and inflammasome activation," *Immunity*, vol. 34, no. 2, pp. 213–223, 2011.

[87] C. J. Hedegaard, C. Enevold, F. Sellebjerg, K. Bendtzen, and C. H. Nielsen, "Variation in NOD2 augments Th2- and Th17 responses to myelin basic protein in multiple sclerosis," *PLoS One*, vol. 6, no. 5, article e20253, 2011.

[88] M. White, G. Webster, D. O’Flammé, C. Guo, J. W. Fulp, Y. Jiang et al., "Interferon-β1a on the effects of IFN-β in patients with multiple sclerosis," *Brain*, vol. 138, no. 3, pp. 644–652, 2015.

[89] M. Inoue, P. H. Chen, S. Siecinski et al., "An interferon-β-resistant and NLRP3 inflammasome-independent subtype of EAE with neuronal damage," *Nature Neuroscience*, vol. 19, no. 12, pp. 1599–1609, 2016.

[90] C. Guo, J. W. Fulp, Y. Jiang et al., "Development and characterization of a hydroxyl-sulfonamide analogue, 5-chloro-N-[2-(4-hydroxysulfamoyl-phenyl)-ethyl]-2-methoxy-benzamide, as a novel NLRP3 inflammasome inhibitor for potential treatment of multiple sclerosis," *ACS Chemical Neuroscience*, vol. 8, no. 10, pp. 2194–2201, 2017.

[91] R. C. Coll, A. A. B. Robertson, J. J. Chae et al., "A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases," *Nature Medicine*, vol. 21, no. 3, pp. 248–255, 2015.

[92] A. Musella, G. Mandolesi, A. Gentile et al., "Cladribine interferes with IL-1β synaptic effects in experimental multiple sclerosis," *Journal of Neuroimmunology*, vol. 264, no. 1-2, pp. 8–13, 2013.

[93] H. Yu, M. Wu, G. Lu et al., "Prednisone alleviates demyelination through regulation of the NLRP3 inflammasome in a C57BL/6 mouse model of cuprizone-induced demyelination," *Brain Research*, vol. 1678, pp. 75–84, 2015.

[94] B. Z. Shao, W. Wei, P. Ke, Z. Q. Xu, J. X. Zhou, and C. Liu, "Activating cannabinoid receptor 2 alleviates pathogenesis of experimental autoimmune encephalomyelitis via activation of autophagy and inhibiting NLRP3 inflammasome," *CNS Neuroscience & Therapeutics*, vol. 20, no. 12, pp. 1021–1028, 2014.

[95] T. Soundara Rajan, S. Giacoppo, F. Diomede, P. Bramanti, O. Trubiani, and E. Mazzone, "Human periodontal ligament stem cells secrete from multiple sclerosis patients suppresses NALP3 inflammasome activation in experimental autoimmune encephalomyelitis," *International Journal of Immunopathology and Pharmacology*, vol. 30, no. 3, pp. 238–252, 2017.

[96] J. R. Hodges, "Alzheimer’s centennial legacy: origins, landmarks and the current status of knowledge concerning cognitive aspects," *Brain*, vol. 129, no. 11, pp. 2811–2822, 2006.

[97] P. Scheltens, K. Blennow, M. M. B. Breteler et al., "Alzheimer’s disease," *The Lancet*, vol. 388, no. 10043, pp. 505–517, 2016.

[98] A. Rubartelli, "DAMP-mediated activation of NLRP3–inflammasome in brain sterile inflammation: the fine line between healing and neurodegeneration," *Frontiers in Immunology*, vol. 5, p. 99, 2014.

[99] A. Salminen, J. Ojala, A. Kauppinen, K. Kaarniranta, and T. Suuronen, "Inflammation in Alzheimer’s disease: amyloid-β oligomers trigger innate immunity defence via pattern recognition receptors," *Progress in Neurobiology*, vol. 87, no. 3, pp. 181–194, 2009.

[100] M. Saresella, F. Ia Rosa, F. Piancone et al., "The NLRP3 and NLRP1 inflammasomes are activated in Alzheimer’s disease," *Molecular Neurodegeneration*, vol. 11, no. 1, p. 23, 2016.

[101] V. Kaushal, R. Dye, P. Pakavathkumar et al., "Neuronal NLRP1 inflammasome activation of caspase-1 coordinately regulates inflammatory interleukin-1-beta production and axonal degeneration-associated caspase-6 activation," *Cell Death & Differentiation*, vol. 22, no. 10, pp. 1676–1686, 2015.

[102] M. T. Heneka, M. P. Kummer, A. Stutz et al., "NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice," *Nature*, vol. 493, no. 7434, pp. 674–678, 2013.

[103] N. Murphy, B. Grehan, and M. A. Lynch, "Gliaal uptake of amyloid beta induces NLRP3 inflammasome formation via cathepsin-dependent degradation of NLRP10," *NeuroMolecular Medicine*, vol. 16, no. 1, pp. 205–215, 2014.

[104] J. M. Rubio-Perez and J. M. Morillas-Ruiz, "A review: inflammatory process in Alzheimer’s disease, role of cytokines," *The Scientific World Journal*, vol. 2012, Article ID 756357, 15 pages, 2012.

[105] L. Liu and C. Chan, "The role of inflammasome in Alzheimer’s disease," *Aging Research Reviews*, vol. 15, pp. 6–15, 2014.

[106] M. Kitazawa, D. Cheng, M. R. Tsukamoto et al., "Blocking IL-1 signaling rescues cognition, attenuates tau pathology, and restores neuronal β-catenin pathway function in an Alzheimer’s disease model," *The Journal of Immunology*, vol. 187, no. 12, pp. 6539–6549, 2011.

[107] J. M. Craft, D. M. Watterson, E. Hirsch, and L. J. van Eldik, "Interleukin 1 receptor antagonist knockout mice show enhanced microglial activation and neuronal damage induced by intracerebroventricular infusion of human β-amyloid," *Journal of Neuroinflammation*, vol. 2, no. 1, p. 15, 2005.

[108] C. Roodveldt, J. Christodoulou, and C. M. Dobson, "Immunological features of α-synuclein in Parkinson’s disease," *Journal of Cellular and Molecular Medicine*, vol. 12, no. 5B, pp. 1820–1829, 2008.

[109] M. G. Spillantini, A. R. Crowther, R. Jakes, M. Hasegawa, and M. Goedert, "α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies," *Proceedings of the National Academy of Sciences*. 
[112] M. Mogi, A. Togari, T. Kondo et al., "Caspase activities and tumor necrosis factor receptor R1 (p55) level are elevated in the substantia nigra from parkinsonian brain," *Journal of Neural Transmission*, vol. 107, no. 3, pp. 335–341, 2000.

[113] T. Nagatsu, M. Mogi, H. Ichinose, and A. Togari, "Changes in cytokines and neurotrophins in Parkinson’s disease," *Journal of Neural Transmission Suplementum*, vol. 60, pp. 277–290, 2000.

[114] P. Zhang, X. Y. Shao, G. J. Qi et al., "Cdk5-dependent activation of neuronal inflammasomes in Parkinson’s disease," *Movement Disorders*, vol. 31, no. 3, pp. 366–376, 2016.

[115] H. Bai, B. Yang, W. Yu, Y. Xiao, D. Yu, and Q. Zhang, "Cathepsin B links oxidative stress to the activation of NLRP3 inflammasome," *Experimental Cell Research*, vol. 362, no. 1, pp. 180–187, 2018.

[116] V. Lawana, N. Singh, S. Sarkar et al., "Involvement of c-Abl kinase in microglial activation of NLRP3 inflammasome and impairment in autolysosomal system," *Journal of Neuroimmune Pharmacology*, vol. 12, no. 4, pp. 624–660, 2017.

[117] H. S. Chun, G. E. Gibson, L. A. DeGiorgio, H. Zhang, V. J. Kidd, and J. H. Son, "Dopaminergic cell death induced by MPP+, oxidant and specific neurotoxocants shares the common molecular mechanism," *Journal of Neurochemistry*, vol. 76, no. 4, pp. 1010–1021, 2001.

[118] P. Klevenyi, O. Andreassen, R. J. Ferrante, J. R. Schleicher Jr., R. M. Friedlander, and M. F. Beal, "Transgenic mice expressing a dominant negative mutant interleukin-1β converting enzyme show resistance to MPTP neurotoxicity," *NeuroReport*, vol. 10, no. 3, pp. 635–638, 1999.

[119] W. Wang, L. T. T. Nguyen, C. Burlak et al., "Caspase-1 causes truncation and aggregation of the Parkinson’s disease-associated protein α-synuclein," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 113, no. 34, pp. 9587–9592, 2016.

[120] C. B. Hurelbrink, R. J. E. Armstrong, L. M. Luheshi, S. B. Dunnett, A. E. Rosser, and R. A. Barker, "Death of dopaminergic neurons in vitro and in nigral grafts: reevaluating the role of caspase activation," *Experimental Neurology*, vol. 171, no. 1, pp. 46–58, 2001.

[121] H. Mochizuki, H. Hayakawa, M. Migita et al., "An AAV-derived Apaf-1 dominant negative inhibitor prevents MPTP toxicity as antiapoptotic gene therapy for Parkinson’s disease," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 98, no. 19, pp. 10918–10923, 2001.

[122] G. Codolo, N. Plotegher, T. Pozzobon et al., "Triggering of inflammasome by aggregated α-synuclein, an inflammatory response in synucleinopathies," *PLoS One*, vol. 8, no. 1, article e55375, 2013.

[123] A. Gustot, J. I. Gallea, R. Sarroukh, M. S. Celej, J. M. Ruysschaert, and V. Raussens, "Amyloid fibrils are the molecular trigger of inflammation in Parkinson’s disease," *Biochemical Journal*, vol. 471, no. 3, pp. 323–333, 2015.